You are viewing the site in preview mode
Skip to main content
|
Factors
|
HBsAg-positive patients (n = 127)
|
HBsAg-negative patients (n = 293)
|
P value
|
|---|
|
No
|
%
|
No
|
%
|
|---|
|
Age > 60
|
22
|
17.3
|
97
|
33.1
|
0.001*
|
|
Gender
| | | | |
0.116*
|
|
Male
|
79
|
62.2
|
158
|
53.9
| |
|
Female
|
48
|
37.8
|
135
|
46.1
| |
|
Bulky mass (≥ 7.5 cm)
|
22
|
17.3
|
52
|
17.7
|
0.916*
|
|
Special sites involvement
| | | | | |
|
Liver
|
6
|
4.7
|
10
|
3.4
|
0.519*
|
|
Spleen
|
28
|
22.0
|
19
|
6.5
|
< .001*
|
|
Stomach
|
11
|
8.6
|
34
|
11.6
|
0.371*
|
|
Intestinal
|
3
|
2.3
|
33
|
11.2
|
0.003*
|
|
Waldeyer’ string
|
26
|
20.5
|
71
|
24.2
|
0.401*
|
|
Bone
|
9
|
7.1
|
12
|
4.1
|
0.196*
|
|
Performance status
| | | | |
0.425*
|
|
0–1
|
115
|
90.6
|
272
|
92.8
| |
|
2–4
|
12
|
9.4
|
21
|
7.2
| |
|
B symptoms present
|
28
|
22.0
|
76
|
26.0
|
0.396*
|
|
Elevated LDH
|
59
|
46.5
|
135
|
46.1
|
0.943*
|
|
Ann Arbor stage
| | | | |
0.028*
|
|
I–II
|
55
|
43.3
|
161
|
54.9
| |
|
III–IV
|
72
|
56.7
|
132
|
45.1
| |
|
Extra-nodal sites ≥ 2
|
22
|
17.3
|
49
|
16.7
|
0.880*
|
|
IPI score
| | | | |
0.653*
|
|
0–1
|
103
|
81.1
|
232
|
79.2
| |
|
3–5
|
24
|
18.9
|
61
|
20.8
| |
|
Use of rituximab
|
60
|
47.2
|
143
|
48.8
|
0.769*
|
|
Response to chemotherapy
| | | | |
0.300†
|
|
Complete response
|
78
|
61.4
|
196
|
66.9
| |
|
Partial response
|
40
|
31.5
|
83
|
28.3
| |
|
Stable disease
|
1
|
0.8
|
4
|
1.4
| |
|
Progressive disease
|
7
|
5.5
|
10
|
3.4
| |
|
Not available
|
1
|
0.8
|
0
|
0.0
| |
- IPI International Prognostic Index, LDH lactate dehydrogenase
- *χ2 test for independence in HBsAg-positive compared with HBsAg-negative patients
- †Fisher exact test for independence in HBsAg-positive compared with HBsAg-negative patients
